Company: NCEL
Filing Date: 2025-08-29
Form Type: 425
Source: 0001213900-25-082554
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-08-29
Form: 425
Chunk 3
---
otherwise, are contained in the F-4 Registration Statement and other relevant materials to be filed with the SEC regarding the proposed
transaction when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available
before making any voting or investment decisions. You may obtain free copies of these documents from the Company using the sources indicated
above.

<div align='center'>EXHIBIT INDEX</div>

<div align='center'>2

SIGNATURES</div>

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

| Date: August 29, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:----------------------|:-----------------------|:--------------------|:------------------------|
|                       |                        | Name:               | Alexander Zwyer         |
|                       |                        | Title:              | Chief Executive Officer |

<div align='center'>3</div>

Exhibit 99.1

<div align='center'>SEVENTH AMENDMENT TO

AGREEMENT OF MERGER AND PLAN OF REORGANIZATION</div>

This Seventh Amendment to
Agreement of Merger and Plan of Reorganization (this “”) is made and entered into as of August 29, 2025, by
and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “”), NLS Pharmaceutics
Ltd., a corporation incorporated under the laws of Switzerland (“”), and NLS Pharmaceuticals (Israel) Ltd., an
Israeli company (“”, and together with the Company and Parent, the “”). Capitalized
terms used herein without definition shall have the same definition ascribed thereto in the Agreement (as defined below).

WHEREAS, the Agreement
of Merger and Plan of Reorganization was made and entered into as of November 4, 2024, as amended as of January 30, 2025, as further amended
as of February 17, 2025, as further amended as of May 5, 2025, as further amended on June 5, 2025, and as further amended as of July 1,
2025, and as further amended on July 18, 2025, by and among the Company, Parent and Merger Sub (the “”);

WHEREAS